{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:14:46Z","timestamp":1789852486638,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.urology.2012.04.032","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T08:00:49Z","timestamp":1339574449000},"page":"736.e7-736.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic Pheochromocytomas"],"prefix":"10.1016","volume":"80","author":[{"given":"Alcides","family":"Chaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Brimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda","family":"Gonzalez-Roibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Argani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2012.04.032_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.surg.2008.02.007","article-title":"Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle\/apoptosis gene expression analysis","volume":"143","author":"Strong","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.urology.2012.04.032_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urology.2012.04.032_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1196\/annals.1353.049","article-title":"Malignant pheochromocytoma: state of the field with future projections","volume":"1073","author":"Ahlman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.urology.2012.04.032_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urology.2012.04.032_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1634\/theoncologist.2008-0043","article-title":"Pheochromocytoma: current approaches and future directions","volume":"13","author":"Adler","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.urology.2012.04.032_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","article-title":"Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center","volume":"39","author":"Szalat","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.urology.2012.04.032_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-0029-1231025","article-title":"Treatment of malignant pheochromocytoma","volume":"41","author":"Adjall\u00e9","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.urology.2012.04.032_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/archinte.1985.00360020211041","article-title":"Streptozotocin therapy for malignant pheochromocytoma","volume":"145","author":"Gross","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.urology.2012.04.032_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1210\/jc.2006-1544","article-title":"Clinical review: current treatment of malignant pheochromocytoma","volume":"92","author":"Scholz","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2012.04.032_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jcem-73-1-18","article-title":"Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1\/P-glycoprotein) which is also expressed by adrenocortical carcinomas","volume":"73","author":"Bates","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2012.04.032_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urology.2012.04.032_bib12","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/cncr.25502","article-title":"Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy","volume":"116","author":"Schultz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2012.04.032_bib13","first-page":"3895","article-title":"Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells","volume":"56","author":"Seufferlein","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2012.04.032_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2012.04.032_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2012.04.032_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/bj20020838","article-title":"Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells","volume":"368","author":"Harthill","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.urology.2012.04.032_bib17","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1152\/ajpendo.00035.2011","article-title":"Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2\/AKT\/mTOR\/S6K1 pathways through modulation of Bcl-2 and BAD","volume":"302","author":"Saito","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.urology.2012.04.032_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urology.2012.04.032_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.urology.2012.04.032_bib20","first-page":"89","article-title":"Practical methods for tissue microarray construction","volume":"103","author":"Fedor","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.urology.2012.04.032_bib21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0b013e31822895e5","article-title":"Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas","volume":"35","author":"Schultz","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urology.2012.04.032_bib22","unstructured":"Chaux A, Schultz L, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol. (In press)."},{"key":"10.1016\/j.urology.2012.04.032_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.urology.2012.04.032_bib24","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/en.2011-0052","article-title":"Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127","volume":"152","author":"Jiang","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.urology.2012.04.032_bib25","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.urology.2012.04.032_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0046-8177(98)90070-3","article-title":"Prognostic markers in pheochromocytoma","volume":"29","author":"Clarke","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urology.2012.04.032_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.urology.2006.02.019","article-title":"Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas","volume":"68","author":"Gao","year":"2006","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512004360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512004360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:55:40Z","timestamp":1758765340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429512004360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090429512004360"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2012.04.032","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic Pheochromocytomas","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2012.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}